Zobrazeno 1 - 10
of 17
pro vyhledávání: '"John Edward Janik"'
Autor:
Mikayel Mkrtichyan, Pankaj Gaur, John Edward Janik, Stacey L. Bjorgaard, Samir N. Khleif, Genevieve M. Boland, Moshe Sade-Feldman, Seema Gupta, Ming Tan, Phillip Wong, Rahul Nandre, Rajeev K Shrimali, Scott A. Hammond, Shamim Ahmad, Gad Getz, José A. López, Jedd D. Wolchok, Nir Hacohen, Hua Wang, Taha Merghoub, Vivek Verma, Keren Yizhak, Jennifer A. Wargo, Sumin Lu, Winjie Dai, Keith T. Flaherty, Jingjing Qi, Ryan J. Sullivan
Publikováno v:
Nature Immunology. 20:1231-1243
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance, while PD-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4e7690faeabda6c38af13c989fcd033
https://doi.org/10.1038/s41590-019-0441-y
https://doi.org/10.1038/s41590-019-0441-y
Autor:
John D. Powderly, Martin Gutierrez, Judy S. Wang, Erika P. Hamilton, Manish Sharma, Alexander I. Spira, Michael Millward, Mark J. Shackleton, Sophia Frentzas, Marianna Koczywas, Naveen Mehta, Ann Marie Christensen, Irina Shapiro, Kerry Whalen, Jennifer Michaelson, Patrick Baeuerle, John Edward Janik, Drew W. Rasco
Publikováno v:
Journal of Clinical Oncology. 40:TPS2688-TPS2688
TPS2688 Background: The major histocompatibility complex (MHC) class I-related proteins MICA and MICB are stress-inducible, surface glycoproteins that are up-regulated on human tumors. MICA/MICB are ligands for the activating receptor, Natural Killer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3625b8fa9cb63b322955ff6b3e73cd98
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2688
https://doi.org/10.1200/jco.2022.40.16_suppl.tps2688
Autor:
Helena Alexandra Yu, Daniel Shao-Weng Tan, Egbert F. Smit, Alexander I. Spira, Ross A. Soo, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M. Wrangle, Mark A. Socinski, Marianna Koczywas, David Witter, Asher Page, Leigh Zawel, John Edward Janik, Zofia Piotrowska
Publikováno v:
Journal of Clinical Oncology. 40:9007-9007
9007 Background: EGFR ins20-mutant NSCLC has historically been challenging to treat. While new agents targeting EGFR ins20 have recently been approved, adverse events (AEs), particularly wild type (WT) EGFR-related AEs are common. CLN-081 is a novel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95cd63937d0cc38607bc59ebac050715
https://doi.org/10.1200/jco.2022.40.16_suppl.9007
https://doi.org/10.1200/jco.2022.40.16_suppl.9007
Autor:
Sudha Ananth, Shamim Ahmad, Takumi Kumai, Samir N. Khleif, Esteban Celis, Rasha Abu Eid, Zuzana Berrong, Paulo C. Rodriguez, Rajeev K. Shrimali, Yuan Lin, John Edward Janik, Mason Webb, Mikayel Mkrtichyan
Publikováno v:
Cancer Research. 77:4135-4145
Inhibition of specific Akt isoforms in CD8+ T cells promotes favored differentiation into memory versus effector cells, the former of which are superior in mediating antitumor immunity. In this study, we investigated the role of upstream PI3K isoform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7b393ff34616d47c72fa67283847fea
https://doi.org/10.1158/0008-5472.can-16-1925
https://doi.org/10.1158/0008-5472.can-16-1925
Autor:
Mario R. Mautino, Ray S. Lin, John Edward Janik, Eugene P. Kennedy, Andrea Pirzkall, Charles J. Link, Xiaorong Liang, David H. Munn, Sami Mahrus, Bruce McCall, Nicholas N. Vahanian, Laurent Salphati, Zhonglin Hao, Stephanie Royer-Joo, Asha Nayak-Kapoor, Samir N. Khleif, Lisa Marshall, Ramses F. Sadek, W. Jay Ramsey, Kari M. Morrissey, Robin Dobbins
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73fc28cc7c59c4759fd428fd7ccd9573
https://doi.org/10.1186/s40425-018-0351-9
https://doi.org/10.1186/s40425-018-0351-9
Publikováno v:
Immunotherapy. 7:777-792
Novel strategies for cancer treatment involving blockade of immune inhibitors have shown significant progress toward understanding the molecular mechanism of tumor immune evasion. The preclinical findings and clinical responses associated with progra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0421feef14a987618b1f61898d257d11
https://doi.org/10.2217/imt.15.49
https://doi.org/10.2217/imt.15.49
Autor:
Pankaj Gaur, Harlan Robins, Seema Gupta, Shamim Ahmad, Erik Yusko, Catherine Sanders, Vivek Verma, Rachel M. Gittelman, Rajeev K. Shrimali, Peng Zeng, Mikayel Mkrtichyan, Samir N. Khleif, Sudha Ananth, Scott A. Hammond, John Edward Janik
Publikováno v:
Cancer immunology research. 5(9)
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1) together with immune stimulatory agonist Abs like anti-OX40 are being tested in the clinic to achieve improved antitumor effects. Here,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::753f04db25bd77642fc248bec9853a1f
https://pubmed.ncbi.nlm.nih.gov/28848055
https://pubmed.ncbi.nlm.nih.gov/28848055
Autor:
Samir N. Khleif, Adelaida Matevosyan, Mikayel Mkrtichyan, John Edward Janik, Eslam Mohamed, Rajeev K. Shrimali, Zuzana Berrong, Rasha Abu Eid, Shamim Ahmad, Mason Webb, Scott A. Hammond, Grigori Okoev
Publikováno v:
Cancer immunology research. 6(2)
Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to escape immune surveillance via multiple immune suppressive mechanism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da7faae5215909dd2e5617d0c773f9c8
https://pubmed.ncbi.nlm.nih.gov/29305519
https://pubmed.ncbi.nlm.nih.gov/29305519
Autor:
Keren Yizhak, Jennifer A. Wargo, Nir Hacohen, Moshe Sade-Feldman, Shamim Ahmad, John Edward Janik, Genevieve M. Boland, Winjie Dai, Jingjing Qi, Vivek Verma, Gad Getz, José A. López, Taha Merghoub, Samir N. Khleif, Scott A. Hammond, Hua Wang, Seema Gupta, Sumin Lu, Jedd D. Wolchok, Phillip Wong, Pankaj Gaur, Keith T. Flaherty, Ming Tan, Rahul Nandre, Stacey L. Bjorgaard, Rajeev K Shrimali, Mikayel Mkrtichyan, Ryan J. Sullivan
Publikováno v:
Nature Immunology. 20:1555-1555
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::004fef05184afd90d59ab5f98622dc2a
https://doi.org/10.1038/s41590-019-0519-6
https://doi.org/10.1038/s41590-019-0519-6
Autor:
John Edward Janik, Ghazaleh Shoja E Razavi, Samir N. Khleif, Mikayel Mkrtichyan, Rasha Abu Eid
Publikováno v:
Cancer immunology research. 4(5)
Cancer immunotherapy has proven to be a potent treatment modality. Although often successful in generating antitumor immune responses, cancer immunotherapy is frequently hindered by tumor immune-escape mechanisms. Among immunosuppressive strategies w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c136b9293de85fc69998dd1a00c52a6
https://pubmed.ncbi.nlm.nih.gov/27196429
https://pubmed.ncbi.nlm.nih.gov/27196429